- Home
- CHKP vs BIIB Comparison
CHKP vs BIIB Comparison
Compare CHKP & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHKP | BIIB |
|---|---|---|
| Founded | 1993 | 1978 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 27.1B |
| IPO Year | 1997 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CHKP | BIIB |
|---|---|---|
| Price | $153.56 | $183.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 27 |
| Target Price | ★ $213.18 | $194.72 |
| AVG Volume (30 Days) | ★ 1.4M | 827.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.79 |
| Revenue | N/A | ★ $9,890,600,000.00 |
| Revenue This Year | $8.28 | N/A |
| Revenue Next Year | $6.03 | N/A |
| P/E Ratio | ★ $17.05 | $21.03 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $150.17 | $110.04 |
| 52 Week High | $234.36 | $202.41 |
Technical Indicators
Market Signals| Indicator | CHKP | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 46.95 |
| Support Level | $150.17 | $181.24 |
| Resistance Level | $166.31 | $186.17 |
| Average True Range (ATR) | 3.95 | 5.30 |
| MACD | 0.51 | -1.14 |
| Stochastic Oscillator | 23.73 | 16.93 |
Price Performance
Historical ComparisonAbout CHKP Check Point Software Technologies Ltd.
Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).